Citations

Showing 10 of 108104 citations.

Fever, Chest Pain, and Odynophagia: A Clinical Triad of an Infected Esophageal Duplication Cyst
Webb, Lauren M. , Kamboj, Amrit K. , Olave, Maria C. , Guo, Ruifeng, Majumder, Shounak, Majumder, Shounak , Guo, Ruifeng , Majumder, Shounak , Guo, Ruifeng

Mayo Clinic

American Journal of Gastroenterology | May 4, 2022 | Volume: 117 | Issue: 9 | Pages: 1397-1397

10.14309/ajg.0000000000001811 | PMID 35505513 Get It

Clinicopathologic Features of Facial Dermatofibromas, a Cohort Study, and a Systematic Review of Literature
Alsawas, Mouaz , Dundar, Bilge, Alsawas, Mouaz , Prokop, Larry J. , Murad, M. Hassan , Swick, Brian L.

Mayo Clinic

The American Journal of Dermatopathology | May 3, 2022 | Volume: 44 | Issue: 11 | Pages: 822-827

10.1097/dad.0000000000002211 | PMID 35503883 Get It

Background: Dermatofibromas are common skin tumors that typically occur on the extremities and trunk and demonstrate benign behavior, frequent recurrences, and very rare metastasis. Facial dermatofibromas are rare and not well studied. We analyzed clinicopathologic features of facial dermatofibromas. Design: Considering the rarity of the condition, we conducted a cohort study and a systematic review. We queried medical records of a single tertiary care center for dermatofibromas from January 1, 2000, to July 1, 2021. A systematic review of multiple databases was conducted through October 27, 2021, to include studies reporting facial dermatofibromas. Random-effects meta-analysis was used to estimate pooled odds ratio and proportions with associated 95% confidence interval (CI). Results: The cohort study identified 2858 cases of dermatofibromas, of which, 23 cases from 18 patients were on the face (1%). The mean age was 52.7 ± 17.8 years. Fifty-six percent of the cases were women. The most common location was the forehead (6 cases). The mean follow-up was 54 months. Forty-four percent of the cases had subcutaneous involvement, and 39% were the cellular type. Margins were positive in 89% of the cases, recurrence rate was 22%, and no metastases were observed. The systematic review included 10 studies (119 patients). Meta-analyses showed that facial dermatofibromas were 2% of all dermatofibromas (95% CI: 1%–3%). The local recurrence rate was 14% (95% CI: 6%–26%). Facial dermatofibromas with subcutaneous involvement were more likely to recur [odds ratio 4.53 (95% CI: 1.12–18.24)]. Before histopathologic examination, clinical differential diagnosis included dermatofibromas in only 9% of the cases (95% CI: 2%–19%). Conclusion: Facial dermatofibromas are rare and are difficult to fully excise. Cellular type and subcutaneous or muscular involvement are common in these cases and tend to have higher local recurrence rate than other nonfacial dermatofibromas. Wider excisions might be necessary for complete excision.
Additive Manufacturing of Medical Microdevices
Saracaydin, Renc, Hara, Seth A. , Saracaydin, Renc

Mayo Clinic

2022 Design of Medical Devices Conference | May 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2022-1042 Get It

Abstract Additive manufacturing is a growing field, but its application in the fabrication of medical microdevices has not been fully explored. Traditionally, medical microdevices are manufactured via a combination of techniques such as photolithography, laser-cutting, and micromolding, which collectively have challenges such as multiple fabrication steps, limited design freedom, high fabrication cost, and significant fabrication time. Micro vat photopolymerization is presented here as an alternative method to produce four different microscale medical devices that have applications in microfluidics, drug delivery, and bioscaffolding. In terms of minimum feature size and resolution, the presented structures are comparable, if not superior, to literature quoted parts fabricated through conventional manufacturing methods. The fabrication steps, process parameters, design considerations, learnings, and future research directions are outlined.
Deep Unsupervised Clustering of Sparse Echo Data to Identify Patients for Implantation of Cardioverter-Defibrillator
Enayati, Moein , Farahani, Nasibeh Zanjirani , Bos, J. Martijn , Ackerman, Michael J. , Arruda‐Olson, Adelaide M. , Bos, Johan M , Scott, Christopher G. , Yao, Xiaoxi , Ngufor, Che

Mayo Clinic

2022 Design of Medical Devices Conference | May 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2022-1074 Get It

Abstract According to the 2020 report of the American Heart Association’s Heart & Stroke Statistics report, nearly 1,000 people are dying daily because of sudden out-of-hospital cardiac arrests and unfortunately, their survival rate is as low as 10%. Hypertrophic Cardiomyopathy (HCM), a relatively rare genetic heart disease is one of these diseases but finding the right patient for the implantation of ICD is still a research question. Implantation of cardioverter-defibrillator (ICD) can save the life of some of these patients. Due to the complexity of the identification of HCM patients, financial burdens, and the clinical risks involved in the ICD implantation procedure, HCM patients will go into a monitoring state before reaching the implantation trigger. Our study cohort shows about 82% of HCM deaths, did not have an ICD, which highlights the need to improve the pre-screening algorithms. In the current paper, we have proposed a new deep learning-based unsupervised clustering technique to facilitate the prioritization of patients to undergo ICD device implantation. This model uses over 900 echocardiographic measurements to find patients who benefit more from the ICD implantation procedure. Our model was trained and tested over 6 years of echo reports collected at Mayo Clinic. This model can be used as a decision support assistant for cardiologists in finding the right HCM patient when decision-making is hard.
Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions
Wirrell, Elaine , Nabbout, Rima , Scheffer, Ingrid E. , Alsaadi, Taoufik , Bogacz, Alicia, French, Jacqueline A. , Hirsch, Édouard , Jain, Satish, Kaneko, Sunao, Riney, Kate , Snead, O. Carter , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M. , Balestrini, Simona , Wiebe, Samuel , Cross, J. Helen , Perucca, Emilio , Wirrell, Elaine C , Samia, Pauline , Somerville, Ernest , Specchio, Nicola , Trinka, Eugen , Balestrini, Simona , Wiebe, Samuel , Cross, Helen J , Perucca, Emilio , Moshé, Solomon L , Hirsch, Edouard , French, Jacqueline , Scheffer, Ingrid E , Zuberi, Sameer M , Jain, Satish, Samia, Pauline , Trinka, Eugen , Moshé, Solomon L. , Tinuper, Paolo

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1333-1348

10.1111/epi.17237 | PMID 35503715 Get It

AbstractEpilepsy syndromes have been recognized for >50 years, as distinct electroclinical phenotypes with therapeutic and prognostic implications. Nonetheless, no formally accepted International League Against Epilepsy (ILAE) classification of epilepsy syndromes has existed. The ILAE Task Force on Nosology and Definitions was established to reach consensus regarding which entities fulfilled criteria for an epilepsy syndrome and to provide definitions for each syndrome. We defined an epilepsy syndrome as “a characteristic cluster of clinical and electroencephalographic features, often supported by specific etiological findings (structural, genetic, metabolic, immune, and infectious).” The diagnosis of a syndrome in an individual with epilepsy frequently carries prognostic and treatment implications. Syndromes often have age‐dependent presentations and a range of specific comorbidities. This paper describes the guiding principles and process for syndrome identification in both children and adults, and the template of clinical data included for each syndrome. We divided syndromes into typical age at onset, and further characterized them based on seizure and epilepsy types and association with developmental and/or epileptic encephalopathy or progressive neurological deterioration. Definitions for each specific syndrome are contained within the corresponding position papers.
Introduction to the epilepsy syndrome papers
Wirrell, Elaine , Perucca, Emilio , Perucca, Emilio , Moshé, Solomon L , Wirrell, Elaine C , Tinuper, Paolo , Moshé, Solomon L.

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1330-1332

10.1111/epi.17262 | PMID 35503711 Get It

International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions
Riney, Kate , Bogacz, Alicia, Somerville, Ernest , Hirsch, Édouard , Nabbout, Rima , Scheffer, Ingrid E. , Zuberi, Sameer M. , Alsaadi, Taoufik , Jain, Satish, French, Jacqueline A. , Specchio, Nicola , Wiebe, Samuel , Cabral‐Lim, Leonor , Naidoo, Ansuya , Perucca, Emilio , French, Jacqueline , Trinka, Eugen , Wiebe, Samuel , Auvin, Stéphane , Perucca, Emilio , Moshé, Solomon L , Wirrell, Elaine C , Hirsch, Edouard , Scheffer, Ingrid E , Somerville, Ernest , Specchio, Nicola , Zuberi, Sameer M , Jain, Satish, Trinka, Eugen , Auvin, Stéphane , Moshé, Solomon L. , Wirrell, Elaine , Tinuper, Paolo

Mayo Clinic

Epilepsia | May 3, 2022 | Volume: 63 | Issue: 6 | Pages: 1443-1474

10.1111/epi.17240 | PMID 35503725 Get It

AbstractThe goal of this paper is to provide updated diagnostic criteria for the epilepsy syndromes that have a variable age of onset, based on expert consensus of the International League Against Epilepsy Nosology and Definitions Taskforce (2017–2021). We use language consistent with current accepted epilepsy and seizure classifications and incorporate knowledge from advances in genetics, electroencephalography, and imaging. Our aim in delineating the epilepsy syndromes that present at a variable age is to aid diagnosis and to guide investigations for etiology and treatments for these patients.
Clinical Management of Metastatic Hormone Receptor-Positive, HER2-negative Breast Cancer (MBC) After CDK 4/6 inhibitors: A Retrospective Single-Institution Study
Choong, Grace M. , Liddell, S. , Leon‐Ferre, Roberto A. , O’Sullivan, Ciara C. , Ruddy, Kathryn J. , Haddad, Tufia C. , Hobday, Timothy J. , Peethambaram, Prema P. , Liu, Minetta C. , Choong, Grace M , Goetz, Matthew P. , Giridhar, Karthik V.

Mayo Clinic

No container title available | May 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1601792/v1 Get It

Abstract Purpose Cyclin dependent kinase 4/6 inhibitors (CDK4/6is), in combination with endocrine therapy (ET), are standard either in the first (1L) or second line (2L) setting for the treatment of hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC). However, the optimal sequencing of treatments after progression on CDK4/6i remains unknown. We performed a single institution analysis to identify treatments and outcomes after progression on a CDK4/6i. Methods We identified patients with HR-positive, HER2-negative MBC prescribed a CDK4/6i in the 1L or 2L settings from December 2014-February 2018 at Mayo Clinic in Rochester, Minnesota. Outcomes were collected through September 30, 2020. Results Palbociclib, in combination with letrozole or fulvestrant, was the most prescribed CDK4/6i. The 1L and 2L CDK4/6i cohorts exhibited comparable overall survival (OS), but progression free survival (PFS) was longer in the 1L than the 2L cohort [28.2 months (95% CI 19.6–34.9) vs 19.8 months (95% CI 15.7–29.6)]. The most common post-CDK4/6i treatments were PI3K/mTOR inhibitors (PI3K/mTORi), single agent ET, or chemotherapy. PFS in the 1L CDK4/6i cohort following PI3K/mTORi was 8.5 months (95% CI 5.5 months – NE), single-agent ET was 6.0 months (95% CI 3.3–14.0 months), and chemotherapy PFS was 5.4 months (95% CI 3.3 months- NE). Conclusions Following progression on a CDK 4/6i, mPFS was short, with similar PFS times comparing chemotherapy and ET, with slightly longer PFS for targeted strategies (PI3K/mTOR). These results highlight a major need to better understand the mechanisms of CDK4/6i resistance and identify new therapeutic strategies for these patients.
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Aizer, Ayal A. , Lamba, Nayan , Ahluwalia, Manmeet S. , Aldape, Kenneth , Boire, Adrienne , Brown, Paul D. , Camidge, D. Ross , Chiang, Veronica , Davies, Michael A. , Hu, Leland , Huang, Raymond Y. , Kumthekar, Priya , Lam, Keng , Lee, Eudocia Q. , Parsons, Michael , Reardon, David A. , Sheehan, Jason P. , Tawbi, Hussein A. , Weller, Michael , Wen, Patrick Y. , Kaufmann, Timothy, Kumthekar, Priya , Parsons, Michael W , Soffietti, Riccardo , Tawbi, Hussein , Weller, Michael , Ahluwalia, Manmeet S , Huang, Raymond , Brastianos, Priscilla K. , Kaufmann, Timothy J. , Lin, Nancy U. , Mehta, Minesh P. , Soffietti, Riccardo , Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | May 3, 2022 | Volume: 24 | Issue: 10 | Pages: 1613-1646

10.1093/neuonc/noac118 | PMID 35762249 Get It

Abstract Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is known about brain metastases than cancer-related entities of similar incidence. Advances in oncologic care have heightened the importance of intracranial management. Here, in this consensus review supported by the Society for Neuro-Oncology (SNO), we review the landscape of brain metastases with particular attention to management approaches and ongoing efforts with potential to shape future paradigms of care. Each coauthor carried an area of expertise within the field of brain metastases and initially composed, edited, or reviewed their specific subsection of interest. After each subsection was accordingly written, multiple drafts of the manuscript were circulated to the entire list of authors for group discussion and feedback. The hope is that the these consensus guidelines will accelerate progress in the understanding and management of patients with brain metastases, and highlight key areas in need of further exploration that will lead to dedicated trials and other research investigations designed to advance the field.
Non-Invasive Diagnosis of Deep Vein Thrombosis to Expedite Treatment and Prevent Pulmonary Embolism During Gestation
Maiti, Dolly, Arunachalam, S P , Arunachalam, Shivaram P.

Mayo Clinic

2022 Design of Medical Devices Conference | May 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1115/dmd2022-1054 Get It

Abstract Deep vein thrombosis (DVT) is the formation of thrombosis or blood clot in the deep veins of the body, usually in the lower extremities or pelvic vein. During this time, a hypercoagulable state results in a higher rate of deep vein thrombosis (DVT) and pulmonary embolism (PE) during gestation and the postnatal stage. PE is the leading cause of maternal death, making early diagnosis and clinical treatment vital to both the mother’s and fetal life. The current technologies for the diagnosis of DVT reduced detection accuracy with increased depth, false negatives when parallel veins are present, and the incompetence of imaging due to factors such as obesity and edema. The drawback of compression ultrasound is that clots may emboli during diagnosis and travel to vital organs such as the heart. In this study a new technological advancement is explored to superior diagnostic methods, and a near infrared device will be able to provide relative measurements of the oxygenation levels of calf veins and can help identify excessive deoxygenation and specific locations. Oxyhemoglobin & deoxyhemoglobin absorbs red light and infra-red lights differently. Oxygenated blood gets absorbed by IR light while deoxygenated gets transmitted. When infrared light is emitted onto a vein, it gets absorbed by the oxygenated hemoglobin and gives an absorbance ratio of output to the input close to 1. Infrared radiation spectroscopy measurements can indicate Δ½HbO2 and Δ½Hb to show a comparison, helping to indicate the presence or absence of a clot. . The circuit is designed with capacitors, resistors, and transistors to act as filters and triggers to pulsate at 20Hz, to pick up biological signals. An Arduino Uno microcontroller helped to process data in order to analyze signal proximity to 0 or 1 to classify DVT and validate the efficacy of using IR for DVT detection Testing of the device allowed for a functionality check to understand whether it was able to pick up signals of oxygenation levels. The 3 tests have insight on the potential of the device; however, the results were inconclusive, due to a lack of sufficient testing. The limitation has been the inability to test on a large sample size and insufficient data, therefore it can’t be said for now whether IR is an effective way of diagnosing DVT. However, since on localized testing, the device seems to be gathering programmed signals, the research can be furthered, and the efficacy can be proved by testing on expecting patients.